No survival benefit from adding chemotherapy to adjuvant radiation in advanced major salivary gland cancer
Abstract This study aimed to compare survival of patients with advanced major salivary gland cancers treated with adjuvant chemoradiation therapy (CRT) versus radiotherapy (RT) alone, after surgical resection. The Taiwan Cancer Registry database was used to identify patients (2009–2017) with advance...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2022-12-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-022-25468-9 |
| _version_ | 1811315525215584256 |
|---|---|
| author | Nai-Wen Kang Yu-Hsuan Kuo Hung-Chang Wu Chung-Han Ho Yi-Chen Chen Ching-Chieh Yang |
| author_facet | Nai-Wen Kang Yu-Hsuan Kuo Hung-Chang Wu Chung-Han Ho Yi-Chen Chen Ching-Chieh Yang |
| author_sort | Nai-Wen Kang |
| collection | DOAJ |
| description | Abstract This study aimed to compare survival of patients with advanced major salivary gland cancers treated with adjuvant chemoradiation therapy (CRT) versus radiotherapy (RT) alone, after surgical resection. The Taiwan Cancer Registry database was used to identify patients (2009–2017) with advanced (T3–4 or nodal positivity) major salivary gland cancers, treated post-surgically with adjuvant CRT or RT alone. Overall survival (OS) and disease-specific survival (DSS) evaluated using Kaplan–Meier. Stratified analyses conducted on clinicopathological features. A total of 395 patients were analyzed: 178 (45.1%) received adjuvant CRT; 217 (54.9%) received adjuvant RT alone. Median radiation dose was 66 Gy in 33 fractions. Cisplatin was most common chemotherapy regimen. After a median follow-up of 3.37 years, there was no significant difference in OS or DSS (p = 0.1354 and 0.3361, respectively) between groups. Adding chemotherapy to adjuvant RT was not significantly associated with improved OS (adjusted hazard ratio [aHR] 0.94; 95% CI 0.72–1.23) and DSS (aHR 0.96; 95% CI 0.72–1.28). Stratified analysis of clinicopathological features found no significant advantages for improved OS or DSS from adding chemotherapy to adjuvant RT. Thus, in this population database, the use of chemotherapy provided limited survival benefits in advanced major salivary gland cancers after surgical resection. |
| first_indexed | 2024-04-13T11:32:52Z |
| format | Article |
| id | doaj.art-426248e163be4e449fa36ba64a3cf79f |
| institution | Directory Open Access Journal |
| issn | 2045-2322 |
| language | English |
| last_indexed | 2024-04-13T11:32:52Z |
| publishDate | 2022-12-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj.art-426248e163be4e449fa36ba64a3cf79f2022-12-22T02:48:32ZengNature PortfolioScientific Reports2045-23222022-12-0112111010.1038/s41598-022-25468-9No survival benefit from adding chemotherapy to adjuvant radiation in advanced major salivary gland cancerNai-Wen Kang0Yu-Hsuan Kuo1Hung-Chang Wu2Chung-Han Ho3Yi-Chen Chen4Ching-Chieh Yang5Division of Hematology and Oncology, Department of Internal Medicine, Chi Mei Medical CenterDivision of Hematology and Oncology, Department of Internal Medicine, Chi Mei Medical CenterDivision of Hematology and Oncology, Department of Internal Medicine, Chi Mei Medical CenterDepartment of Medical Research, Chi Mei Medical CenterDepartment of Medical Research, Chi Mei Medical CenterDepartment of Radiation Oncology, Chi Mei Medical CenterAbstract This study aimed to compare survival of patients with advanced major salivary gland cancers treated with adjuvant chemoradiation therapy (CRT) versus radiotherapy (RT) alone, after surgical resection. The Taiwan Cancer Registry database was used to identify patients (2009–2017) with advanced (T3–4 or nodal positivity) major salivary gland cancers, treated post-surgically with adjuvant CRT or RT alone. Overall survival (OS) and disease-specific survival (DSS) evaluated using Kaplan–Meier. Stratified analyses conducted on clinicopathological features. A total of 395 patients were analyzed: 178 (45.1%) received adjuvant CRT; 217 (54.9%) received adjuvant RT alone. Median radiation dose was 66 Gy in 33 fractions. Cisplatin was most common chemotherapy regimen. After a median follow-up of 3.37 years, there was no significant difference in OS or DSS (p = 0.1354 and 0.3361, respectively) between groups. Adding chemotherapy to adjuvant RT was not significantly associated with improved OS (adjusted hazard ratio [aHR] 0.94; 95% CI 0.72–1.23) and DSS (aHR 0.96; 95% CI 0.72–1.28). Stratified analysis of clinicopathological features found no significant advantages for improved OS or DSS from adding chemotherapy to adjuvant RT. Thus, in this population database, the use of chemotherapy provided limited survival benefits in advanced major salivary gland cancers after surgical resection.https://doi.org/10.1038/s41598-022-25468-9 |
| spellingShingle | Nai-Wen Kang Yu-Hsuan Kuo Hung-Chang Wu Chung-Han Ho Yi-Chen Chen Ching-Chieh Yang No survival benefit from adding chemotherapy to adjuvant radiation in advanced major salivary gland cancer Scientific Reports |
| title | No survival benefit from adding chemotherapy to adjuvant radiation in advanced major salivary gland cancer |
| title_full | No survival benefit from adding chemotherapy to adjuvant radiation in advanced major salivary gland cancer |
| title_fullStr | No survival benefit from adding chemotherapy to adjuvant radiation in advanced major salivary gland cancer |
| title_full_unstemmed | No survival benefit from adding chemotherapy to adjuvant radiation in advanced major salivary gland cancer |
| title_short | No survival benefit from adding chemotherapy to adjuvant radiation in advanced major salivary gland cancer |
| title_sort | no survival benefit from adding chemotherapy to adjuvant radiation in advanced major salivary gland cancer |
| url | https://doi.org/10.1038/s41598-022-25468-9 |
| work_keys_str_mv | AT naiwenkang nosurvivalbenefitfromaddingchemotherapytoadjuvantradiationinadvancedmajorsalivaryglandcancer AT yuhsuankuo nosurvivalbenefitfromaddingchemotherapytoadjuvantradiationinadvancedmajorsalivaryglandcancer AT hungchangwu nosurvivalbenefitfromaddingchemotherapytoadjuvantradiationinadvancedmajorsalivaryglandcancer AT chunghanho nosurvivalbenefitfromaddingchemotherapytoadjuvantradiationinadvancedmajorsalivaryglandcancer AT yichenchen nosurvivalbenefitfromaddingchemotherapytoadjuvantradiationinadvancedmajorsalivaryglandcancer AT chingchiehyang nosurvivalbenefitfromaddingchemotherapytoadjuvantradiationinadvancedmajorsalivaryglandcancer |